Press Releases
- Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
- Annual General Meeting of Active Biotech AB
- FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
- Annual Report 2021 Active Biotech AB (publ)
- Active Biotech strengthens the patent protection for laquinimod in eye disorders